

Profile

Ipsen is a leading global biopharmaceutical company focused on Innovation and Specialty Care, which develops and commercializes medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease.

Offering a broad range of high-quality, innovative treatments to help improve the lives of patients with cancer, Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, breast cancer, neuroendocrine tumors, medullary thyroid cancer, hepatocellular carcinoma, bladder cancer, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business.

Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 35 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.). The company has more than 5,700 employees worldwide.



2019 Key Figures

20+ drugs marketed
in more than
115 countries

More than **4/5** of
sales generated by
specialty **care drugs**

Invested
**€ 389 million in
R&D**

representing about
15.1% of sales

5,700+ employees
worldwide



For more information on Ipsen, visit www.ipсен.com.

ALL-ALL-0023 1 1

ALL-DE-000531

December 2020